Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Cost-effectiveness
77%
Tuberculosis
75%
COVID-19
67%
Transmission Dynamics
64%
Vaccination
64%
Epidemiology
56%
Pandemic Influenza Virus
51%
United Kingdom
48%
Chlamydia
48%
Low Burden
48%
School Closure
48%
Latent Tuberculosis Infection
41%
Surveillance Data
41%
Influenza
37%
Health Care Services
37%
Sexually Transmitted Infections
36%
A(H1N1)pdm09
35%
Economic Evaluation
32%
Migrants
32%
Molecular Diagnostics
32%
Mathematical Modeling
32%
Tuberculosis Diagnosis
32%
Critical Care
32%
Clearance Rate
32%
Great Britain
32%
Influenza Pandemic
32%
Care Provision
32%
Reassortment
32%
Mycoplasma Genitalium
32%
Chlamydia Trachomatis Infection
32%
Public Health Impact
32%
Contact Pattern
29%
Risk Behavior
29%
Cross-immunity
29%
Intensive Care Unit
28%
Mathematical Model
27%
COVID-19 Pandemic
27%
Infection Rate
26%
European Countries
26%
Natural History
25%
Drug Resistance
25%
Quality-adjusted Life Years
25%
Seasonal Influenza
24%
Antiviral Drugs
24%
Epidemiological Characteristics
24%
Whole Genome Sequencing
24%
Sex Work
23%
Contact Diary
22%
Confidence Interval
22%
Primary Care
22%
Medicine and Dentistry
Health Care Cost
100%
Cost-Effectiveness Analysis
82%
Public Health
66%
Pandemic Influenza
48%
Intensive Care Unit
48%
COVID-19
44%
Infection
43%
Primary Health Care
42%
2009 H1N1 Influenza
37%
Latent Tuberculosis
35%
Intensive Care
35%
Health Service
34%
Household
32%
Mycoplasma genitalium
32%
Quality Adjusted Life Year
28%
Chlamydiae
25%
Pelvic Inflammatory Disease
23%
Human Immunodeficiency Virus
22%
Observational Study
21%
Whole Genome Sequencing
21%
Urethritis
21%
High Risk Behavior
20%
Gonorrhea
19%
Cohort Analysis
19%
Men Who Have Sex with Men
18%
Randomized Controlled Trial
18%
Interferon Gamma Release Assay
18%
Severe Acute Respiratory Syndrome Coronavirus 2
16%
Systematic Review
16%
Dynamic Modeling
16%
Meta-Analysis
16%
Patient Referral
16%
Lymphogranuloma Venereum
16%
Molecular Diagnosis
16%
Prenatal Care
16%
Recurrent Infection
16%
Tuberculosis Diagnosis
16%
Antiviral Drug
16%
Emergency Department
16%
Acute HIV Infection
16%
Chlamydia Infection
16%
Cluster Randomized Trial
16%
Antibiotic Resistance
16%
Rifapentine
16%
Influenza A
16%
Diagnostic Testing
16%
Pandemic
16%
Targeted Therapy
16%
Drug Resistance
16%
Reinfection
15%
